- Home
- PSF vs VNDA Comparison
PSF vs VNDA Comparison
Compare PSF & VNDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSF
- VNDA
- Stock Information
- Founded
- PSF 2010
- VNDA 2002
- Country
- PSF United States
- VNDA United States
- Employees
- PSF N/A
- VNDA N/A
- Industry
- PSF Investment Managers
- VNDA Biotechnology: Pharmaceutical Preparations
- Sector
- PSF Finance
- VNDA Health Care
- Exchange
- PSF Nasdaq
- VNDA Nasdaq
- Market Cap
- PSF 251.0M
- VNDA 249.4M
- IPO Year
- PSF N/A
- VNDA 2006
- Fundamental
- Price
- PSF $20.87
- VNDA $5.49
- Analyst Decision
- PSF
- VNDA Strong Buy
- Analyst Count
- PSF 0
- VNDA 2
- Target Price
- PSF N/A
- VNDA $16.50
- AVG Volume (30 Days)
- PSF 25.0K
- VNDA 495.7K
- Earning Date
- PSF 01-01-0001
- VNDA 11-05-2025
- Dividend Yield
- PSF 7.69%
- VNDA N/A
- EPS Growth
- PSF N/A
- VNDA N/A
- EPS
- PSF N/A
- VNDA N/A
- Revenue
- PSF N/A
- VNDA $203,467,000.00
- Revenue This Year
- PSF N/A
- VNDA $15.45
- Revenue Next Year
- PSF N/A
- VNDA $37.82
- P/E Ratio
- PSF N/A
- VNDA N/A
- Revenue Growth
- PSF N/A
- VNDA 11.78
- 52 Week Low
- PSF $16.00
- VNDA $3.81
- 52 Week High
- PSF $20.19
- VNDA $5.55
- Technical
- Relative Strength Index (RSI)
- PSF 55.83
- VNDA 67.52
- Support Level
- PSF $20.82
- VNDA $5.22
- Resistance Level
- PSF $21.04
- VNDA $5.48
- Average True Range (ATR)
- PSF 0.21
- VNDA 0.21
- MACD
- PSF -0.01
- VNDA 0.06
- Stochastic Oscillator
- PSF 58.12
- VNDA 90.31
About PSF Cohen & Steers Select Preferred and Income Fund Inc.
Cohen & Steers Select Preferred and Income Fund Inc is a diversified, closed-end investment company. The Fund's primary investment objective is high current income with capital appreciation as its secondary objective. The Fund invests at least of its Managed Assets in preferred and other income securities issued by U.S. and non-U.S. companies.
About VNDA Vanda Pharmaceuticals Inc.
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.